Literature DB >> 30361849

Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease.

Giuseppe Lopalco1, Vincenzo Venerito2, Luca Cantarini3, Giacomo Emmi4, Domenico Prisco4, Florenzo Iannone2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30361849     DOI： 10.1007/s11739-018-1970-3

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  11 in total

1.  A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.

Authors:  Bente Glintborg; Inge Juul Sørensen; Anne Gitte Loft; Hanne Lindegaard; Asta Linauskas; Oliver Hendricks; Inger Marie Jensen Hansen; Dorte Vendelbo Jensen; Natalia Manilo; Jakob Espesen; Mette Klarlund; Jolanta Grydehøj; Sabine Sparre Dieperink; Salome Kristensen; Jimmi Sloth Olsen; Henrik Nordin; Stavros Chrysidis; Dorte Dalsgaard Pedersen; Michael Veedfald Sørensen; Lis Smedegaard Andersen; Kathrine Lederballe Grøn; Niels Steen Krogh; Lars Pedersen; Merete Lund Hetland
Journal:  Ann Rheum Dis       Date:  2017-05-04       Impact factor: 19.103

Review 2.  Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.

Authors:  Jürgen Braun; Alex Kudrin
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 3.  Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease.

Authors:  Luca Cantarini; Giuseppe Lopalco; Francesco Caso; Luisa Costa; Florenzo Iannone; Giovanni Lapadula; Maria Grazia Anelli; Rossella Franceschini; Cristina Menicacci; Mauro Galeazzi; Carlo Selmi; Donato Rigante
Journal:  Autoimmun Rev       Date:  2014-08-22       Impact factor: 9.754

Review 4.  Behçet's syndrome pathophysiology and potential therapeutic targets.

Authors:  Giacomo Emmi; Elena Silvestri; Danilo Squatrito; Mario Milco D'Elios; Lucia Ciucciarelli; Domenico Prisco; Lorenzo Emmi
Journal:  Intern Emerg Med       Date:  2014-01-12       Impact factor: 3.397

5.  Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet's disease after switching from infliximab originator.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Emanuele Cassarà; Olga Kaloudi
Journal:  Eur J Rheumatol       Date:  2017-10-25

Review 6.  Behçet syndrome: a contemporary view.

Authors:  Hasan Yazici; Emire Seyahi; Gulen Hatemi; Yusuf Yazici
Journal:  Nat Rev Rheumatol       Date:  2018-01-03       Impact factor: 20.543

7.  Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.

Authors:  Shigeaki Ohno; Satoshi Nakamura; Sadao Hori; Machiko Shimakawa; Hidetoshi Kawashima; Manabu Mochizuki; Sunao Sugita; Satoki Ueno; Kazuyuki Yoshizaki; Goro Inaba
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666

8.  Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease.

Authors:  Giuseppe Lopalco; Orso Maria Lucherini; Antonio Lopalco; Vincenzo Venerito; Claudia Fabiani; Bruno Frediani; Mauro Galeazzi; Giovanni Lapadula; Luca Cantarini; Florenzo Iannone
Journal:  Front Immunol       Date:  2017-02-27       Impact factor: 7.561

9.  Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.

Authors:  Antonio Vitale; Giacomo Emmi; Giuseppe Lopalco; Stefano Gentileschi; Elena Silvestri; Claudia Fabiani; Maria Letizia Urban; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Donato Rigante; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2016-09-27       Impact factor: 3.650

10.  A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.

Authors:  Dae Hyun Yoo; Artur Racewicz; Jan Brzezicki; Roman Yatsyshyn; Edgardo Tobias Arteaga; Asta Baranauskaite; Carlos Abud-Mendoza; Sandra Navarra; Vladimir Kadinov; Irmgadt Goecke Sariego; Seung Suh Hong; Sung Young Lee; Won Park
Journal:  Arthritis Res Ther       Date:  2016-04-02       Impact factor: 5.156
View more
  4 in total

1.  Behçet's syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments.

Authors:  Giacomo Emmi; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2019-07-17       Impact factor: 3.397

Review 2.  Advances in the Treatment of Behcet's Disease.

Authors:  Fatma Alibaz-Oner; Haner Direskeneli
Journal:  Curr Rheumatol Rep       Date:  2021-05-20       Impact factor: 4.592

3.  The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors.

Authors:  Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Arianna Sgheri; Giuseppe Lopalco; Jurgen Sota; Silvana Guerriero; Florenzo Iannone; Bruno Frediani; Lorenzo Vannozzi; Maria Teresa Bianco; Valtere Giovannini; Gian Marco Tosi; Luca Cantarini
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

Review 4.  Recent Insights into the Management of Behçet Syndrome.

Authors:  Yesim Ozguler; Ayse Ozdede; Gulen Hatemi
Journal:  J Inflamm Res       Date:  2021-07-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.